secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-021988
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus gets $35M upfront from Gilead to collaborate on up to 4 inflammatory disease targets
--------------------------------------------------------------------------------

- Upfront payment of $35M from Gilead Sciences under Amendment No. 2 to existing collaboration.
- Arcus will conduct research on up to 4 jointly selected targets for inflammatory diseases.
- If Gilead exercises early option on first 2 programs, Arcus eligible for up to $420M in option/milestone payments plus tiered royalties per program.
- For other option exercises, parties co-develop/co-commercialize in US with cost and profit sharing.
- Gilead has two prespecified time points to exercise options for each program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023021988/0000950170-23-021988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023021988/rcus-20230515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer